Drug Name: Sohonos

Indications: To reduce the volume of new heterotopic ossification in adults and pediatric patients (aged 8 years and older for females and 10 years and older for males) with fibrodysplasia ossificans progressive.

Active Ingredient: Palovarotene

Company: Ipsen Biopharmaceuticals, Inc

Approval Date: 8/16/2023

More Details: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215559s000lbl.pdf

Leave a Reply

Your email address will not be published. Required fields are marked *